MedPath

Mind Medicine, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
$507.3M
Website

A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)

Phase 3
Recruiting
Conditions
Major Depressive Disorder
Interventions
Other: Placebo
Drug: MM120 (LSD D-Tartrate)
First Posted Date
2025-04-24
Last Posted Date
2025-04-24
Lead Sponsor
Mind Medicine, Inc.
Target Recruit Count
140
Registration Number
NCT06941844
Locations
🇺🇸

Preferred Research Partner, Fayetteville, Arkansas, United States

🇺🇸

Preferred Research Partners, Inc, Little Rock, Arkansas, United States

🇺🇸

Kadima Neuropsychiatry Institute, La Jolla, California, United States

and more 18 locations

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

Phase 3
Recruiting
Conditions
Generalized Anxiety Disorder
Interventions
Other: Placebo
Drug: MM120 (LSD D-Tartrate)
First Posted Date
2025-02-05
Last Posted Date
2025-05-20
Lead Sponsor
Mind Medicine, Inc.
Target Recruit Count
250
Registration Number
NCT06809595
Locations
🇺🇸

Preferred Research Partners, Inc., Little Rock, Arkansas, United States

🇺🇸

New School Research, Los Angeles, California, United States

🇺🇸

West Los Angeles VA Medical Center, Los Angeles, California, United States

and more 12 locations

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)

Phase 3
Recruiting
Conditions
Generalized Anxiety Disorder
Interventions
Other: Placebo
Drug: MM120 (LSD D-Tartrate)
First Posted Date
2024-12-18
Last Posted Date
2025-05-18
Lead Sponsor
Mind Medicine, Inc.
Target Recruit Count
200
Registration Number
NCT06741228
Locations
🇺🇸

Accel Research Sites - Lakeland CRU, Lakeland, Florida, United States

🇺🇸

Lighthouse Psychiatry, Gilbert, Arizona, United States

🇺🇸

Summit Headlands LLC, Portland, Oregon, United States

and more 25 locations

A Dose-Finding Study of MM-120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

Phase 2
Completed
Conditions
Anxiety Generalized
Interventions
Other: Placebo
Drug: MM-120 (LSD D-Tartrate)
First Posted Date
2022-06-07
Last Posted Date
2025-03-20
Lead Sponsor
Mind Medicine, Inc.
Target Recruit Count
198
Registration Number
NCT05407064
Locations
🇺🇸

Irvine Center for Clinical Research, Irvine, California, United States

🇺🇸

Lutheran Hospital - Cleveland Clinic, Cleveland, Ohio, United States

🇺🇸

iResearch Atlanta, Decatur, Georgia, United States

and more 17 locations

Safety and Efficacy of Low Dose MM-120 for ADHD Proof of Concept Trial

Phase 2
Completed
Conditions
Attention Deficit Disorder
ADHD
Interventions
Other: Placebo
First Posted Date
2022-01-21
Last Posted Date
2025-04-13
Lead Sponsor
Mind Medicine, Inc.
Target Recruit Count
53
Registration Number
NCT05200936
Locations
🇳🇱

Maastricht University, Maastricht, Netherlands

🇨🇭

University Hospital Basel, Basel, Switzerland

A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers

Phase 1
Completed
Conditions
Addiction
Interventions
Drug: 18-MC Compound
First Posted Date
2020-03-03
Last Posted Date
2022-01-05
Lead Sponsor
Mind Medicine, Inc.
Target Recruit Count
108
Registration Number
NCT04292197
Locations
🇦🇺

Dr. Sam Salman, Perth, Australia

© Copyright 2025. All Rights Reserved by MedPath